Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 12/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763074 | 0.91 | NPC1 (0.36) | CA12CA9CHRM2ALDH1A1TSHR | |
| Formic Acid SCHEMBL27230851 | 0.90 | CA12 (0.33) | CA12CA2CA3CA4CA6 | |
| SCHEMBL1934062 | 0.83 | ALDH1A1 (0.43) | KDM4AKDM4CALDH1A1TSHRKDM5A | |
| SCHEMBL9702710 | 0.83 | CA12 (0.36) | CA12CA2CA3CA4CA6 | |
| SCHEMBL25330808 | 0.81 | ALDH1A1 (0.55) | KDM4AKDM4CALDH1A1TSHRKDM5A | |
| Hydrochloric Acid SCHEMBL9701593 | 0.81 | CA12 (0.35) | CA12CA2CA3CA4CA6 | |
| SCHEMBL20756157 | 0.80 | CHRM1 (0.41) | CA12CA9MAPTCHRM2CHRM4 | |
| SCHEMBL21111523 | 0.80 | — | — | |
| SCHEMBL21815374 | 0.79 | NOS3 (0.38) | KDM4AKDM4CALDH1A1TSHRKDM5A | |
| SCHEMBL28903229 | 0.79 | NOS3 (0.38) | CA12CA9ALDH1A1TDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462594-A | Pradienolide compound and application thereof | 卫材R&D管理有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-9707202-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2017-07-18 | — | — | US | claimed |
| US-20160303066-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2016-10-20 | — | — | US | claimed |
| US-9328081-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20150072984-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-03-12 | — | — | US | claimed |
| US-8614211-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2013-12-24 | — | — | US | claimed |
| WO-2013033250-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-03-07 | — | — | WO | claimed |
| US-20130040945-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2013-02-14 | — | — | US | claimed |
| WO-2013023145-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-02-14 | — | — | WO | claimed |
| EP-1126846-B1 | Use of a nicotine receptor agonist for the manufacture of a medicament for the treatment of obsessive compulsive disorder | CARLSSON A RESEARCH AB (SE) | 2003-08-06 | — | — | EP | claimed |
| CN-1139427-A | Malarial aspartic protease inhibitors | SEARLE & CO (US) | 1997-01-01 | — | — | CN | claimed |
| US-5227401-A | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G. D. SEARLE & CO. (US) | 1993-07-13 | — | — | US | claimed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119462594-A | Pradienolide compound and application thereof | 卫材R&D管理有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4365175-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | Spark Biopharma, Inc. (KR) | 2024-05-08 | — | — | EP | disclosed |
| US-20230137764-A1 | PRODRUGS OF FULVESTRANT | ACQUIOM AGENCY SERVICES, AS COLLATERAL AGENT | 2023-05-04 | — | — | US | disclosed |
| WO-1993009108-A1 | AMINO ACYL AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0518819-A2 | Amidino compounds, their manufacture and use as medicament | CIBA-GEIGY AG (CH) | 1992-12-16 | — | — | EP | disclosed |
| US-4966916-A | DI-AND TRIMETHYLAMINOETHYL BENZOATES, PHENYLCARBAMATES AND PHENYLTHIOCARBAMATES | UNIVERSITY OF ROCHESTER | 1990-10-30 | — | — | US | disclosed |
| US-4835162-A | 3-QUINUCLIDINYL BENZOATE OR METHYL CARBAMATE | UNIVERSITY OF ROCHESTER | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137764-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, ESR1 | CA12 2237/4885CA2 3502/4885CA3 1726/4885 |
| US-20150072984-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | VHL, SDHA, TP53 | CA12 413/4885CA2 1030/4885CA3 3215/4885 |
| US-20130040945-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RXRG, ARNT, RARS2 | CA12 986/4885CA2 2121/4885CA3 2298/4885 |
| US-20160303066-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | VHL, SDHA, TP53 | CA12 413/4885CA2 1030/4885CA3 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.